Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | P2RY10 | O00398 | 8/20 | 0.38 |
| ▸ | GPR174 | Q9BXC1 | 4/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963349 | 0.90 | PLA2G2C (0.41) | PLA2G2CP2RY10GPR174GPR34 | |
| SCHEMBL4444982 | 0.89 | PLA2G2C (0.44) | PLA2G2CP2RY10FFAR4FFAR1ALDH1A1 | |
| SCHEMBL4435691 | 0.89 | PLA2G2C (0.44) | PLA2G2CP2RY10FFAR4FFAR1ALDH1A1 | |
| SCHEMBL1965773 | 0.89 | PLA2G2C (0.44) | PLA2G2CP2RY10FFAR4FFAR1ALDH1A1 | |
| SCHEMBL2311014 | 0.89 | PLA2G2C (0.44) | PLA2G2CP2RY10FFAR4FFAR1ALDH1A1 | |
| SCHEMBL1963907 | 0.89 | PLA2G2C (0.44) | PLA2G2CP2RY10FFAR4FFAR1ALDH1A1 | |
| SCHEMBL2841915 | 0.87 | PLA2G2C (0.41) | PLA2G2CP2RY10GPR174FFAR4FFAR1 | |
| SCHEMBL2842565 | 0.87 | PLA2G2C (0.41) | PLA2G2CP2RY10GPR174FFAR4FFAR1 | |
| SCHEMBL752259 | 0.79 | PLA2G2C (0.46) | PLA2G2C | |
| SCHEMBL1962712 | 0.79 | PLA2G2C (0.43) | PLA2G2CP2RY10GPR174GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010052718-A9 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-06-16 | — | — | WO | disclosed |